GBA1 and depressive symptom measurement: Three studies published by the same group with 2–6 years of follow-up data of a combined cohort of heterozygous GBA1NMC and biallelic Morbus Gaucher patients with subgroup analyses of the subgroup of heterozygous GBA1 cohort alone, found more deterioration in scales of depression, RBD, olfaction, global cognition (MoCA) as well as MDS-UPDRS part II and III scores in the GBA1NMC group compared to GBA1wildtype12–14.